Drug news
Roche revives development of gantenerumab in Phase III trial for mild Alzheimer's-related dementia
Roche is to revive the development of gantenerumab after it had failed to improve cognition or function compared to placebo in the now discontinued SCARLET ROAD trial for Alzheimer's disease. This drug is directed at beta amyloid toxic plaques which many believe may be the cause of Alzheimer's disease.The company initiated a new trial Phase III in May 2014 called MARGUERITE ROAD using a higher dose in patients with mild Alzheimer's-related dementia which will extend over 24 months.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.